MedPath

COLLABORATIVE MEDICINAL DEVELOPMENT PTY LIMITED

🇦🇺Australia
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

6

Active:0
Completed:4

Trial Phases

2 Phases

Phase 1:4
Phase 2:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
4 (66.7%)
Phase 2
2 (33.3%)

Treatment Continuation Study for Patients With ALS/MND Who Completed Study CMD-2019-001

Phase 2
Completed
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2020-03-18
Last Posted Date
2022-02-17
Lead Sponsor
Collaborative Medicinal Development Pty Limited
Target Recruit Count
55
Registration Number
NCT04313166
Locations
🇦🇺

Macquarie University, Macquarie Park, New South Wales, Australia

CuATSM Compared With Placebo for Treatment of ALS/MND

Phase 2
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebos
First Posted Date
2019-09-09
Last Posted Date
2019-11-06
Lead Sponsor
Collaborative Medicinal Development Pty Limited
Target Recruit Count
80
Registration Number
NCT04082832
Locations
🇦🇺

Macquarie University, Macquarie, New South Wales, Australia

Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease

Phase 1
Completed
Conditions
Parkinson Disease
Interventions
First Posted Date
2017-07-02
Last Posted Date
2020-03-17
Lead Sponsor
Collaborative Medicinal Development Pty Limited
Target Recruit Count
31
Registration Number
NCT03204929
Locations
🇦🇺

Macquarie University, Macquarie Park, New South Wales, Australia

🇦🇺

The Royal Melbourne Hospital, Melbourne, Victoria, Australia

ALS Treatment Extension Study

Phase 1
Conditions
Amyotrophic Lateral Sclerosis
Interventions
First Posted Date
2017-05-02
Last Posted Date
2022-02-17
Lead Sponsor
Collaborative Medicinal Development Pty Limited
Target Recruit Count
28
Registration Number
NCT03136809
Locations
🇦🇺

Macquarie University, Sydney, New South Wales, Australia

Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND

Phase 1
Completed
Conditions
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Interventions
First Posted Date
2016-08-17
Last Posted Date
2020-03-17
Lead Sponsor
Collaborative Medicinal Development Pty Limited
Target Recruit Count
50
Registration Number
NCT02870634
Locations
🇦🇺

Macquarie University, Sydenham, New South Wales, Australia

🇦🇺

Calvary Health Care Bethlehem, Caulfield, Victoria, Australia

  • Prev
  • 1
  • 2
  • Next

News

No news found
© Copyright 2025. All Rights Reserved by MedPath